Basil22, I believe you probably answered your own question on this. "The standard strategy for small biotechs is to do the r/s and then sell more shares to raise capital."
Personally I don't want a r/s as it would destroy my and others positions. But (IMHO) I am expecting one before this is all through as no company is going to pay full price for this in a buy out as things stand right now or if they file the IND and move toward a clinical they will likely have to do a r/s to raise $$$ for it.
Either way I am expecting a r/s before we get to clinicals.